I only saw the abstract of this one. There was a study that found that taking anti-TNF drugs, in this case infliximab (i.e. Remicade), reduced the occurrence of mycobacterium avium paratuberculosis (MAP) bacteria in people suffering from Crohn's. Specifically, they just measured the change in MAP antibodies in the blood, but it would suggest that Remicade supported the body's fight against any MAP infection. I've had a couple posts on MAP, so I like to monitor research in this area. Interesting finding that supports the efficacy of these drugs (although admittedly I don't take them).
Thursday, May 6, 2010
Anti-TNF Decreases Presence of MAP
I only saw the abstract of this one. There was a study that found that taking anti-TNF drugs, in this case infliximab (i.e. Remicade), reduced the occurrence of mycobacterium avium paratuberculosis (MAP) bacteria in people suffering from Crohn's. Specifically, they just measured the change in MAP antibodies in the blood, but it would suggest that Remicade supported the body's fight against any MAP infection. I've had a couple posts on MAP, so I like to monitor research in this area. Interesting finding that supports the efficacy of these drugs (although admittedly I don't take them).
Subscribe to:
Post Comments (Atom)
6-MP (mercaptopurine) is strongly antimicrobial against MAP.
ReplyDeleteOn the Action of Methotrexate and 6-Mercaptopurine on
M.avium Subspecies paratuberculosis
Robert J. Greenstein1*, Liya Su1, Vahram Haroutunian2, Azra Shahidi3, Sheldon T. Brown4
1 Laboratory of Molecular Surgical Research, VA Medical Center, Bronx, New York, United States of America, 2 Psychiatry, VA Medical Center, Bronx,
New York, United States of America, 3 Microbiology, VA Medical Center, Bronx, New York, United States of America, 4 Infectious Diseases, VA Medical
Center, Bronx, New York, United States of America
Thanks for the info!
ReplyDelete